Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Research Field

Research Field Cell & gene therapy

Now For the High-Hanging Fruit

| Miguel Forte

We should be thrilled with the success of the approved CD-19 CAR-T therapies. But the field is still young, and we are only scratching the surface.

Research Field Gene Editing

Dinner with a CRISPR Connoisseur

| Jonathan James

Harvard Medical School’s Richard Sherwood digs into the potential and pitfalls of gene editing technology.

Research Field Drug discovery

DONs Potential Unfolds

| Jonathan James

How DNA origami nanostructures could find their way into the treatment of acute kidney injury.

Research Field Cell & molecular biology

H(eye) - or Low?

| Phoebe Harkin

Two chemical components; opposite effects. How medical marijuana impacts glaucoma for better – and for worse.

Research Field Neuroscience

Building up to a breakthrough

| Jonathan James

We sat down with David Eidelberg shortly after the publication of his group’s most recent paper in Science Translational Medicine.

Research Field Drug discovery

The Power To Change Lives

| Stephanie Sutton

Sitting Down With… Danny Bar-Zohar, Global Head of Neuroscience Development at Novartis, Switzerland.

Research Field Drug discovery

Bearfaced Research

| Roisin McGuigan

A new method for discovering antibiotics makes use of an unusual source of complex microbial communities: bear saliva.

Research Field Immunology

Not Immune to Damage

| Ruth Steer

Could activated T cells play a major role in driving neurodegeneration in glaucoma?

Research Field Drug discovery

Antibody About Turn

| Sam Cobb

A promising candidate is on the verge of entering clinical development… What happens when you see an opportunity to make it even better?

Research Field Diagnostics & prognostics

Better Biomarkers for AD R&D

| Carlo Medici

For better diagnosis and monitoring of Alzheimer’s disease, as well as drug R&D, we need to move toward widespread use of MRI biomarker imaging.

Newsletter

Send me the latest from The Translational Scientist.

Sign up now

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register